Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 &mgr;g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 &mgr;g/ml dexamethasone for at least about three weeks.
Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Abstract: Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.
Abstract: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide controlled, sustained drug release for an extended period of time.
Abstract: Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Abstract: Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Abstract: Intraocular administration of drugs such as .alpha.-2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with systemic administration, concentrates the drug at the site of the disease, and, where microcapsules are employed, provides continuous, long-lasting treatment.
Type:
Grant
Filed:
September 28, 1994
Date of Patent:
May 27, 1997
Assignee:
Oculex Pharmaceuticals, Inc.
Inventors:
Vernon G. Wong, King Y. Lee, Jerry B. Gin
Abstract: Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drags is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.